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Virus-associated human cancers provide unique opportunities for preventive strategies. The role of human papilloma viruses (HPV 16 and 18),
hepatitis B virus (HBV), Epstein-Barr herpes virus (EBV), and retroviruses (human immunodeficiency virus [HIVI and human T-cell
leukemia/lymphoma virus [HTLVI) in the development of common carcinomas and lymphomas represents a major cancer threat, particularly among
individuals residing in developing countries, which account for 80% of the world's population. Even though these viruses are not the sole etiological
agents of these cancers (as would be the case for infectious diseases), different approaches can be implemented to significantly decrease the
incidence of virus-associated malignancies. The first approach is vaccination, which is available for HBV and possibly soon for EBV. The long delay
between primary viral infection and development of associated tumors as well as the cost involved with administering vaccinations detracts from
the feasibility of such an approach within developing countries. The second approach is to increase efforts to detect pre-cancerous lesions or early
tumors using immunovirological means. This would allow early diagnosis and better treatment. The third strategy is linked to the existence of
disease susceptibility genes, and suggests that counseling be provided for individuals carrying these genes to encourage them to modify their
lifestyles and other conditions associated with increased cancer risks (predictive oncology). Specific recommendations include: a) increase
international studies that explore the causes of the large variations in prevalence of common cancers throughout the world; b) conduct
interdisciplinary studies involving laboratory investigation and social sciences, which may suggest hypotheses that may then be tested
experimentally; and c) promote more preventive and health enhancement strategies in addition to curative and replacement therapies. - Environ
Health Perspect 103(Suppl 8):269-273 (1995)
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Origin and Cause
of Human Cancers
To assess possible preventive strategies
linked to the role ofviruses in the causing
human malignancies, one should reassess
the role ofoncogenic viruses in the frame-
work of a multifactorial etiology ofdegen-
erative diseases. In the Pasteurian notion of
the causative agents ofinfectious diseases, a
microbe is the necessary and sufficient etio-
logical factor. Since malignant diseases are
noncontagious, it has been difficult to con-
ceive that infectious agents could play a
crucial role in their development. From the
time that observations of avian leukemias
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and sarcomas were made by Ellerman and
Bang, and Rous early this century to the
present, a large body ofdata has accumu-
lated that establishes a strong association
between a number ofexogenous oncogenic
viruses and the development of tumorous
processes in many animal species and man.
Doubts persist among many researchers
regarding the role ofviruses as etiological
agents of certain human cancers. This is
partially because for a given tumor such as
Burkitt's lymphoma (BL), the strength of
the viral association may vary between geo-
graphical areas, and also because ofthe lack
of a unifying concept for the molecular
processes involved, both in experimental
systems in man. These doubts reflect a
lack of appreciation for the differences
between the epidemiological concepts of
origin and causation in the development
ofdegenerative diseases (1).
The origin ofa malignant disease lies in
the irreversible and hereditary mutations
occurring in expanding cellular clones that
the organism neither recognizes as foreign
nor rejects for other causes. On the other
hand, it is well recognized that oncogenesis
is a multistep process that takes years or
even decades and involves successive gene
disturbances and somatic mutations at the
cellular level.
In epidemiology causation ofdegenera-
tive diseases involves various factors that
are linked to a significant increase in the
incidence ofthe associated diseases or to a
significant decrease after their eradication.
Etiologic and risk factors-both ofwhich
are causative-have a great deal ofpractical
value for the field ofpublic health, since
the removal ofany ofcausal factors (either
necessary and sufficient or significant risk
factors) may potentially lead to partial or
complete prevention ofthe disease.
Finally, it is well established that differ-
ent oncogenic factors associated with tumor
development do not add to but multiply
their effect; for example, the combined
effect ofalcohol and tobacco on the patho-
genesis ofesophagus cancer in Brittany (2),
and Epstein-Barr herpes virus (EBV) and
malaria on the development of BL (3).
Thus, it clearly is a priority to work to
remove at least one ofthese factors, which
has the potential ofsignificantly decreasing
the incidence ofthe associated tumor.
Epidemiologic Importance
ofViral-associated
Human Cancers
Doll and Peto (4), in their estimates
regarding the avoidable risks of cancer in
the United States, considered that about
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10% of human tumors were associated
with viruses. Ifone considers, however, the
sizes of at-risk populations and not the
proportion ofvirus-associated malignancies
among all human tumors, a more accurate
and urgent view is apparent.
Table 1 presents estimates for the pri-
mary virus-associated malignancies experi-
enced in tropical and developing countries.
Based on these data, viruses with onco-
genic potential pose a threat to 80% ofthe
world population, which is the percentage
of individuals residing in the developing
world. When establishing cancer research
and treatment priorities, it must be
remembered that approximately 5 million
women in the world are affected by cervical
carcinoma, which is associated with human
papilloma virus (HPV). Hepatocellular car-
cinoma, which has been etiologically
linked to hepatitis B virus, is responsible
for the deaths ofapproximately 500,000
persons each year in tropical areas despite
the existence ofan efficient viral HBV vac-
cine for 15 years. This has primarily been a
result ofthe inability ofthe Western World
to produce an affordable vaccine for those
with the greatest need. Nasopharyngeal
carcinoma (NPC), which is a major cause
ofcancer-related death in Southeast Asia-
more than 100,000 deaths a year are
attributed to this cancer-exemplifies the
potential effect that successful strategies for
viral infection prevention can illicit.
Finally, tumors developing in acquired
immunodeficiency disease syndrome
(AIDS) patients, which consist of lym-
phomas, Kaposi's sarcomas, and genital
carcinomas, are increasing in relative fre-
quency at the same time that better control
of opportunistic infections is being
achieved. This presents new challenges and
suggests different priorities for biomedical
researchers. High priority should be
attached to comparative studies of these
tumors among individuals with AIDS and
those who do not have AIDS. In addition,
the variations in incidence ofthese tumors
bygeographical area should beexplored.
EBV-associated Malignancies:
A Model
EBV is a ubiquitous gamma herpes virus
that infects both epithelial cells ofthe oro-
nasopharynx, where it replicates, and lym-
phoid B cells, where it remains latent in
vivo, for the entire lifespan. The keypatho-
genic event for this ubiquitous, mostly
innocuous, virus lies in the age and severity
ofthe primary infection, which is mainly
transmitted by saliva.
Table 1. Viruses and human malignancies.
Estimated yearly
incidence ofviral-
Type of oncogenic viruses Associated malignancies Population at highest risk associated tumors
Human papilloma virus Genital carcinomas Women in developing countries:
HPV-16, 18... (cervical, penile, anal) >2 billion >5 million
Hepatitis B virus HBV Hepatocellular carcinomas >1 billion intropical regions >500,000
Epstein-Barr virus EBV Burkitt's lymphoma in Africa >50 million
Nasopharyngeal carcinoma >750 million in Southeast Asia, 5 to 10,000
North Africa, Arctic >120,000
Human T-cell lymphotropic AdultT-cell leukemia >1 billion in tropical areas of 5 to 10,000
viruses HTLV-1 and 11 Africa, South America,
SouthwestJapan
Human immunodeficiency Lymphoma
viruses (HIV-1, HIV-2) Kaposi sarcoma >10 million
Genital carcinomas related
to HPV
When primary infection occurs during
adolescence, which is typical in industrial-
ized countries, the predominant resulting
clinical syndrome is infectious mononucle-
osis. This disease is specific to individuals
within high socioeconomic classes, and
clinical recovery is dependent upon the
efficiency of the T-cell-mediated immune
response. Rare cases ofmalignant prolifera-
tions can result from primary infection by
EBV such as non-Hodgkin's lymphomas,
which has been linked to a recessive gene
on chromosome X-the Purtillo syndrome
(5), or Hodgkin's diseases, with an average
latency period of3 years after severe infec-
tious mononucleosis. There is an increased
relative risk of 3 to 4 among those who
contract severe infectious mononucleosis
compared with the risk of Hodgkin's
disease among the general population.
BurkitesLymphoma
A potential, long-delayed consequence of
severe primary infection by EBV is the
African Burkitt's lymphoma (BL), which is
a high-grade malignant lymphoma ofsmall,
uniform, noncleared B lymphocytes. This
lymphoma tests seropositive for CD19,
CD20, and SIg surface markers. It is
endemic to African children between 5 and
9 years ofage, particularly in areas experi-
encing holo- orhyperendemic malaria.
To determine whether EBV was the
primary or passenger virus in the tumorous
B cells, we designed and conducted a major
prospective study in Uganda between 1970
and 1978 that involved 42,000 children
who were tested for EBV between 6
months and 2 years ofage and followed up
for 7 years. The analysis of pre- versus
postdisease sera of the 16 children who
developed BL showed that an early and
severe primary EBV infection during the
first months oflife represented the key viral
event for later development ofthe disease
(6). It is highly probable that the primary
cause ofearly EBV infection is a mother's
saliva and, to a lesser extent, her breast
milk, since 65% ofall African women of
reproductive age shed infectious EB virus in
their saliva, compared with 12% ofwomen
in the western world. The "feeding kiss"
thus may be a major route oftransmission
for early EBVprimary infection.
Another key environmental factor,
namely holoendemic malaria, was first sus-
pected by Burkitt (7). The experimental
data ofMoss et al. (8) showed that severe
malaria burden specifically depressed T-cell
cytotoxic clones recognizing the LYDMA
epitope of the gp 340 viral glycoprotein at
the surface ofthe infected B lymphocytes.
The last oncogenic event in BL pathogene-
sis is caused by a chromosomal transloca-
tion involving the long arm ofchromosome
8 at the 8q24 locus, which is transposed
either to chromosome 14, as in 80% ofthe
cases, or to chromosome 2 or 22. This
translocation exposes the c-myc protoonco-
gene to cis-activation by the immunoglobu-
lin genes ofthe host chromosomes (9).
To determine the relative importance of
each ofthese three independent factors-
virus, parasite, and genetic event-we com-
pared the incidence ofthe disease in three
geographical areas, including: Europe,
where 3% of the childhood tumors are
attributed to BL and only 15% of these
cases being EBV-associated; North Africa,
where EBVinfection occurs early butwhere
malaria is not a burden; and East Africa
where all three factors come into play. If
the genetic activation of the c-myc onco-
gene were considered the necessary and
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sufficient event for the B-cell tumorous
transformation, we calculate that early EBV
infection increases the risk of BL 20-fold
and holoendemic malaria by an additional
10-fold; thus, in the extreme case, a 200-
fold difference in tumor prevalence is
exhibited (10).
This example is critical to assessing the
various possible preventive approaches.
Socioeconomic development in combina-
tion with modifications in cultural and
hygienic habits could reduce the incidence
ofprimary infection ofmany viruses, espe-
cially those transmitted by saliva and breast
feeding. In addition, using a mosquito net
over babies' cribs to prevent multiple mos-
quitoes bites may delay severe malaria
attacks and therefore suppress a key event
in BL pathogenesis. This clearly is an
example of a situation in which lifestyle
modifications can have dramatic effects on
the multifactorial, multistep process of
tumor pathogenesis.
Determinants ofNasopharyngeal
Carcinoma
Undifferentiated carcinoma of the post
nasal space, or nasopharyngeal carcinoma
(NPC), is prevalent in large populations
residing in restricted geographic areas of
south China, northern Africa and the
Arctic circle (11). The serologic and mole-
cular associations between EBV and NPC
were found to be constant among popula-
tions residing in high-, intermediate-, and
low-risk areas (12,13). The constant
association is in sharp contrast to the BL
situation described earlier.
More important was the discovery that
NPC-affected individuals exhibited high
levels of secretory IgA/VCA and IgA/EA
that paralleled the tumorload, as well as the
characterization ofclinical stages ofNPC.
These advances permitted population-based
serologic testing for earlydiagnosis ofNPC.
In the People's Republic ofChina, Zeng et
al. (14,15) implemented large-scale
IgA/VCA seroepidemiological and clinical
surveys ofsymptomless individuals in an
exemplary manner. This testing permitted
diagnosis of NPC at clinical stages where
radiotherapy induced long-term survival
rates-up to 80% 5 years after radiother-
apy. The same IgA/VCA and IgA/EA tests
were also found to be valuable in postradio-
therapy surveillance of NPC patients in
Western countries. A multicenter study
found that after long-term remission, the
IgA/EA serology test was critical to the
detection ofrelapse 6 to 12 months before
anyobservable dinical symptoms (16).
The molecular pathogenesis involving
EBV genes in the transformation of
nasopharyngeal epithelial cells remains an
open question, and in contrast to the BL
situation, EBV genes might act quite late
in the development ofNPC. As suggested
by the IgA data mentioned before, local
reactivity of latent EBV infection in
nasopharyngeal mucosa precedes clinical
symptoms by months, or even years. These
specific secretory IgA may induce a shift in
EBV lymphotropism toward epitheliotro-
pism (17). Ifthis is the case, the detection
ofIgA/VCA and IgA/EA antibodies origi-
nating in the nasopharynx would indicate
emergence ofpre-NPC tumorous clones.
The majority of these clones, which are
low-grade tumors, could be recognized and
rejected by the organism, thus paralleling
the loss ofthe IgA marker.
Needfor EnvironmentalFactors. The
strong ethnic link between NPC and
Cantonese Chinese, Maghrebian Arabs,
and Greenland Eskimos, suggests a role for
environmental factors in its development
and based on anthropological studies, it
was proposed that traditional preserved
foods consumed by these three widely dif-
ferent ethnic groups could be involved
(18). Chemical carcinogens, genotoxin,
and EBV reactivators were detected in pre-
served meat, fish, and vegetables from the
three areas. Aware that N-nitroso com-
pounds can be formed in the stomach
through nitrosation by bacterial nitrite
reductase enzymes, a case-control study
was implemented in south China using a
urine N-proline test. The results of this
study indicated that healthy individuals
residing in high-risk NPC areas have
significantly higher endogenous nitrosation
rates than healthy persons residing in low-
risk NPC areas (19). Furthermore, the
dietary practices found among individuals
in low-risk NPC areas included high levels
ofvitamin C, which was not true for the
high-risk NPC areas.
At the same time, we screened for com-
pounds that reactivated latent EBV within
the traditional, preserved foods from south
China, northern Africa and the Arctic.
Dried and salted fish from China and tra-
ditional harissa (a spice mixture widely
used in northern Africa) exhibited signifi-
cant EBV replication-inducing activities.
This discovery led to identification of an
active fraction containing a lignin complex
in harissa (20). It is possible that this com-
pound is retained in the Rosenmuller
recesses where, with the presence of
nitrate-reductase bacteria, local reactivation
offormerlylatent EBV takes place.
Genetic Factors in NPCDevelopment.
When sibships with multiple NPC cases
were investigated in an international collab-
orative study involving China, Hong Kong,
Singapore, and Malaysia, evidence pointed
to the existence ofa gene closely linked to
the HLA region ofchromosome 6 that con-
ferred a greatly increased risk (relative
risk=21) for NPC (21). This NPC suscep-
tibility gene has not yet been characterized,
nor has its mode of action, which could
potentially control either the host immune
response to EBV infection or the interme-
diate metabolism ofthe involved chemical
carcinogens mentioned above. The deci-
phering of this interaction between envi-
ronmental and host factors represents a
primary challenge not only for preventing
NPC but for the many human tumors in
whose development both environmental
and genetic factors interact.
Prevention of
Virus-associated Cancers
The goal ofepidemiologists is not just to
test etiologic hypotheses but primarily to
decrease disease incidence through preven-
tive interventions. Early detection ofvirus-
associated tumors such as the strategy
described for NPC led to a dramatic
improvement in the proportion oflong-
term survivors who had received successful
radiotherapy. Individuals residing in
Southeast Asia, who tend to favor preven-
tive actions, areworking to implement early
detection efforts among the large at-risk
population. Chinese individuals are cultur-
ally inclined to assume responsibility to
avoid disease or improve theirhealth. These
individuals are willing to pay for preventive
tests if they believe the tests are directly
beneficial to their health. To this end, a
cost/benefit analysis ofearly NPC detection
should be completed. In contrast, northern
African countries, whose populations tend
not to focus on prevention regarding
healthcare, follow the curative strategies
favored bywestern countries.
Using antiviral vaccines to prevent
virus-associated tumors is a controversial
issue that is the topic of much research.
The primary challenge to a conclusive
evaluation ofthe efficacy ofvaccination is
posed by the long latency period that
elapses between primary infection and
tumor development, which makes the
effects of this preventive intervention
difficult to assess. The second difficulty is
the cost involved in large-scale vaccination.
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The challenges encountered when adminis-
tering a large-scale HBV vaccination pro-
gram within a developing country are
exemplary. The question ofthe necessity of
an EBV vaccine has been repeatedly
addressed, and its value in preventing dis-
eases linked to primary EBV infections is
well-accepted (22). This would involve
prevention ofsevere infectious mononucle-
osis, EBV-associated Hodgkin's diseases,
and X-linked lymphoproliferative syn-
dromes that are, as noted above, linked to
severe primary EBV infection. The value of
vaccination to reduce EBV-associated lym-
phomas emerging among individuals living
with AIDS is more difficult to assess, since
vaccination would occur in latently
infected individuals. The chance to boost
the EBV specific cell-mediated immunity
in these conditions merits investigation.
Administering large-scale EBV vaccines
to prevent African Burkitt's lymphoma is
theoretically ideal. In view of the present
circumstances, however, where 30% of
African newborns die before 5 years ofage
from severe malaria or measles and the pro-
portion ofAIDS-related deaths is dramati-
cally increasing, a vaccination that would
eliminate a tumor that occurs in only 1 of
1000 surviving children appears to be a
low priority.
Regarding NPC, the primary question
is: Would a vaccination administered dur-
ing the first few months of life-before
primary EBV infection-be able to induce
a long-term humoral and cell-mediated
immunity sufficient to protect individuals
for decades? It must be remembered that
these individuals would be environmen-
tally at-risk to develop NPC 25 to 40 years
after being vaccinated. However, adminis-
tering therapeutic EBV vaccines among
IgA/VCA-seropositive individuals who are
at immediate risk for developing NPC
merits consideration.
Conclusions and Proposals
The above examples ofvirus-associated
malignancies and our increasing knowledge
of the multifactorial, multistep carcino-
genic process in humans have practical
applications for both fundamental and
applied cancer research. I suggest three
approaches that could improve our
efficiency in reducing cancer morbidity
and mortality during the coming years.
The first is to widen epidemiologic
studies by investigating more thoroughly
the large variability of specific cancers
throughout the world and to explore
the possible causes of these variations.
American taxpayers wish to concentrate
research efforts on the most common can-
cers in the United States and this is under-
standable. These cancers (breast, colon, and
prostate), however, varywidely in incidence
throughout the world, and comparative
investigation of the putative oncogenic
environmental factors in high- and low-risk
areas for a given cancer could lead to dra-
matic advances in knowledge oftheir etiol-
ogy. In industrialized western countries,
these malignancies are epidemiologically
linked, as evidenced by the similar increases
in the incidence ofall three cancers experi-
enced among Japanese immigrants to U.S.
territories. My first proposal is to develop
internationally collaborative epidemiologi-
cal studies in various locations throughout
the world to study the primary cancers
among U.S. citizens, including those can-
cers associated with HIV-AIDS, which also
exhibit great geographicvariability.
The second recommendation is to
utilize a more interdisciplinary approach
when investigating common cancers. The
results obtained regarding the etiology of
NPC were achieved by collaboration of a
food-habit anthropologist and a chemical
carcinogens group. This interesting case
required examination of common factors
among ethnic groups at high risk ofdevel-
oping NPC instead ofdifferences between
cases and controls. It therefore is becom-
ing increasingly evident that the complex-
ity of interactions between host genetic
factors and environmental carcinogens (i.e.
biological, chemical, or physical factors)
can only be properly investigated through
interdisciplinary studies involving, in addi-
tion to epidemiologists and laboratory
scientists, anthropologists, who investigate
how people live, eat, drink, love, and die.
Practical incentives that promote interdis-
ciplinary approaches to investigating
cancer etiologies should be included
within NCI grant-related activities.
My third proposal is to promote further
shifts in the emphasis of the nation's
approach to health care. In the last 15
years, U.S. citizens have begun to accept
that a preventive approach to health care is
complementary to and to some extent
more cost efficient than curative medicine
and replacement surgery. In addition, the
exponential development of molecular
genetics, which is permitting the characteri-
zation of disease susceptibility genes, is
opening the way for a predictive oncology
that may seal the cultural shift toward
prevention-oriented medical practices.
Considering the prevalent role of
lifestyles, primarily dietary habits, in the
development of common cancers, the
search for specific cancer susceptibility
genes should further cancer prevention in
two ways. The first, which has already been
implemented in a number of specific
genetic counseling centers in the United
States and Europe, is to suggest to carriers
ofspecific disease susceptibility genes that
they participate in screening activities to
ensure early detection ofpretumorous or
tumorous lesions, which may permit cura-
tive treatment (preclinical medicine). The
second is to counsel individuals with specific
genetic traits to modify their lifestyles,
including food habits, to decrease their
cancer-associated risks. Because the interac-
tions of various carcinogenic factors are
multiplicative in their effect and not sim-
ply additive, this preventive attitude could
have a significant effect on several common
cancers, either by decreasing their inci-
dence or by delaying significantly the clini-
cal onset ofthese diseases-perhaps by 7 to
21 years, according to Doll and Peto (4).
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